Podcast | Update on Long-Acting Nebulizers for Guideline-Based Maintenance Treatments for Patients with COPD

Course Title for Certificate

Name*

First NameLast Name

Email*

example@example.com

What best describes your title?*

If PharmD, DOB

Date

If PharmD, NABP ID#:

How many years have you been in practice?

1. According to the 2025 GOLD guidelines, which of the following remains the cornerstone of initial pharmacologic therapy for patients with moderate-to-severe COPD?*

a. Short-acting bronchodilator monotherapyb. Inhaled corticosteroid (ICS) monotherapyc. Long-acting bronchodilator(s), either LAMA or LABAd. Theophylline-based combination therapy

2. The 2025 GOLD guidelines emphasize which key change compared to prior versions in managing exacerbation-prone COPD patients?*

a. Removal of eosinophil count as a guide for ICS useb. Increased preference for dual bronchodilation over ICS/LABA combinationsc. Routine use of systemic corticosteroids for maintenanced. Early initiation of roflumilast in all GOLD Group B patients

3. Which statement best reflects recent clinical trial data regarding nebulized LAMA therapy for COPD?*

a. Nebulized LAMA therapy shows comparable efficacy to handheld options with potential benefits for patients with poor inhaler technique.b. Nebulized LAMA therapy has inferior bronchodilation compared to handheld devices.c. Nebulized LAMA therapy is associated with higher systemic corticosteroid exposure.d. Nebulized LAMA therapy is contraindicated in moderate COPD.

4. In recent randomized trials evaluating nebulized revefenacin for COPD, which outcome was most consistently improved?*

a. Sputum eosinophil reductionb. FEV₁ and trough FEV₁ over 12 weeksc. Weight gain and muscle strengthd. Exacerbation rates within 4 weeks

5. When selecting long-acting nebulized therapy for COPD maintenance, which clinical factor should most influence treatment choice according to GOLD recommendations?*

a. Patient preference for oral versus inhaled therapyb. Insurance formulary coverage onlyc. Ability to generate adequate inspiratory flow with handheld inhalersd. Presence of comorbid allergic rhinitis

6. Which strategy best supports adherence and optimized outcomes with long-acting nebulized COPD maintenance therapy?*

a. Scheduling treatments around exacerbation eventsb. Combining multiple nebulized agents without monitoringc. Limiting therapy to short-term symptom controld. Providing patient education on device cleaning and consistent daily use

How many patients do you currently see each month regarding chronic obstructive pulmonary disease (COPD)?

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Review the updated 2025 GOLD guidelines for the management of patients with moderate-to-severe COPD and their implications for guideline-driven care
Analyze current clinical trial data for LAMA nebulizer therapeutic options to manage COPD
Review clinical strategies to apply guideline- driven long-acting nebulizer treatments for the maintenance of patients with moderate-to-severe COPD

Please provide us with feedback regarding your experience at the activity:

Rows	Poor	Fair	Good	Very Good	Excellent
Overall
Content
Usefulness

Do you feel this activity was fair, balanced, and free of commercial bias?

YesNo

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

YesNoN/A

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

I gained new strategies/skills/information that my team can apply to practiceI plan to implement new strategies/skills/information in my practiceI will be more competent in my team’s management of patient careI will improve my communication with the healthcare team

What factors beyond clinical care that effect the health of your patients does your team experience?

Attestation:

AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits^TM.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Date

Credits